title: Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis.
abstract: OBJECTIVE
  To report the efficacy of intravitreal bevacizumab injection in treatment of macular edema in a case of optic disc vasculitis.
  
  
  METHODS
  Retrospective case review.
  
  
  METHODS
  A patient diagnosed with macular edema due to optic disc vasculitis was treated with intravitreal bevacizumab injection.
  
  
  RESULTS
  One week after injection, fundus appearance dramatically improved and macular edema regressed. The patient was followed up for 1 year after injection and there was no recurrence of macular edema.
  
  
  CONCLUSIONS
  This case suggests that intravitreal bevacizumab treatment might be effective in the management of macular edema in patients with optic disc vasculitis.
authors.affiliation: Department of Ophthalmology, Gülhane Military Medical Academy and Medical School, Etlik, Ankara, Turkey. erdurman@yahoo.com
authors.forename: F Cüneyt
authors.initials: FC
authors.lastname: Erdurman
authors.forename: A Hakan
authors.initials: AH
authors.lastname: Durukan
authors.forename: Tarkan
authors.initials: T
authors.lastname: Mumcuoğlu
authors.forename: Volkan
authors.initials: V
authors.lastname: Hürmeriç
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000150:complications; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009898:Optic Disk / Q000098:blood supply*; D031300:Retinal Vasculitis / Q000150:complications*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab